Login to Your Account



Tonix Pharmaceuticals lands breakthrough status for PTSD drug

By Michael Fitzhugh
Staff Writer

Monday, December 19, 2016

Just months after a phase III trial miss for TNX-102 SL in fibromyalgia elevated PTSD to the lead indication for the Tonix Pharmaceuticals Holding Corp. drug, it has secured FDA breakthrough status in the condition, which is often tied to military combat trauma.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription